Somatostatin receptor scintigraphy in patients with multiple myeloma or plasmocytoma

Somatostatin receptor scintigraphy in patients with multiple myeloma or plasmocytoma - Octreotide scan in multiple myeloma.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON30229

Enrollment

Registered

2007-01-23

Start date

2006-11-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple myeloma plasmacytoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: -Upfront patients with MM that are treated according to the HOVON-49 or HOVON-65 protocol. -Upfront patients with plasmacytoma. -Relapsed MM patients with painful affected areas.

Exclusion criteria

Exclusion criteria: -Radiotherapy lasting longer than 5 days ago in the last 3 months. -Ineligible to perform a scan. -Age under 18 years. -Pregnancy -Severe kidney-dysfunction

Design outcomes

Primary

Measure	Time frame
Study parameters In this pilot study a limited number of patients will be analysed to define whether SRS is a feasible approach for diagnostic or prognostic purposes in MM or plasmacytoma. Thirty newly diagnosed upfront patients and 15 relapsed patients will be investigated. In these patients the following items will be investigated: -To define the sensitivity of SRS in MM and plasmacytoma in comparison to X-ray examination. -To test whether SRS can be used as alternative approach to detect skeleton abnormalities for painful affected areas in the case no abnormalities are observed on X *ray examination. -Correlates the SRS uptake with clinical parameters that defines an aggressive MM and disappear the increased uptake upon treatment with intensive chemotherapy and ASCT and or radiotherapy. Subsequently patients treated according to the Hovon-65 protocol will be re-evaluated after 4 courses of chemotherapy but before the ASCT. Patients with a plasmacytoma will be re-evaluated 2 months after the radiotherapy course.	—

Measure

Time frame

Study parameters In this pilot study a limited number of patients will be analysed to define whether SRS is a feasible approach for diagnostic or prognostic purposes in MM or plasmacytoma. Thirty newly diagnosed upfront patients and 15 relapsed patients will be investigated. In these patients the following items will be investigated: -To define the sensitivity of SRS in MM and plasmacytoma in comparison to X-ray examination. -To test whether SRS can be used as alternative approach to detect skeleton abnormalities for painful affected areas in the case no abnormalities are observed on X *ray examination. -Correlates the SRS uptake with clinical parameters that defines an aggressive MM and disappear the increased uptake upon treatment with intensive chemotherapy and ASCT and or radiotherapy. Subsequently patients treated according to the Hovon-65 protocol will be re-evaluated after 4 courses of chemotherapy but before the ASCT. Patients with a plasmacytoma will be re-evaluated 2 months after the radiotherapy course.

—

Secondary

Measure	Time frame
Not applicable.	—

Countries

Netherlands

Outcome results